Headquartered in Brentwood, TN, just south of Nashville, Melt Pharmaceuticals, Inc. is committed to the development and commercialization of a patented sublingual, needle- and opioid-free procedural sedation and analgesic medication for preoperative use in human medical procedures.
Melt Pharmaceuticals was spun out of Harrow Health (Nasdaq: HROW) in January 2019, after successfully completing our Series A financing.
ImprimisRx (a subsidiary of Harrow Health) and several leading ophthalmologists developed a cGMP compounded version similar to our lead candidate (Melt-300) that has been dispensed more than 100,000 times by over 400 ophthalmologists to patients before cataract surgery. The experience gleaned from physicians and patients with this compounded medication suggests a favorable efficacy and safety profile.
Melt Pharmaceuticals has been granted multiple patents encompassing Melt-300 including those directed at composition of matter and to the methods of using the product. Currently, we are seeking approval for our patented technology through the US Food and Drug Administration’s 505(b)(2) regulatory pathway.
Melt Pharmaceuticals, Inc. is dedicated to improving the ophthalmic surgical patient experience through the development of a new and innovative class of needle- and opioid-free sublingual medications for procedural sedation and analgesia.